Literature DB >> 23717687

An analysis of the sequence variability of meningococcal fHbp, NadA and NHBA over a 50-year period in the Netherlands.

Stefania Bambini1, Jurgen Piet, Alessandro Muzzi, Wendy Keijzers, Sara Comandi, Lisa De Tora, Mariagrazia Pizza, Rino Rappuoli, Diederik van de Beek, Arie van der Ende, Maurizio Comanducci.   

Abstract

Studies of meningococcal evolution and genetic population structure, including the long-term stability of non-random associations between variants of surface proteins, are essential for vaccine development. We analyzed the sequence variability of factor H-binding protein (fHbp), Neisserial Heparin-Binding Antigen (NHBA) and Neisseria adhesin A (NadA), three major antigens in the multicomponent meningococcal serogroup B vaccine 4CMenB. A panel of invasive isolates collected in the Netherlands over a period of 50 years was used. To our knowledge, this strain collection covers the longest time period of any collection available worldwide. Long-term persistence of several antigen sub/variants and of non-overlapping antigen sub/variant combinations was observed. Our data suggest that certain antigen sub/variants including those used in 4CMenB are conserved over time and promoted by selection.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23717687      PMCID: PMC3663754          DOI: 10.1371/journal.pone.0065043

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  60 in total

1.  Distribution of serogroups and genotypes among disease-associated and carried isolates of Neisseria meningitidis from the Czech Republic, Greece, and Norway.

Authors:  Siamak P Yazdankhah; Paula Kriz; Georgina Tzanakaki; Jenny Kremastinou; Jitka Kalmusova; Martin Musilek; Torill Alvestad; Keith A Jolley; Daniel J Wilson; Noel D McCarthy; Dominique A Caugant; Martin C J Maiden
Journal:  J Clin Microbiol       Date:  2004-11       Impact factor: 5.948

2.  Molecular epidemiology of recent belgian isolates of Neisseria meningitidis serogroup B.

Authors:  M Van Looveren; P Vandamme; M Hauchecorne; M Wijdooghe; F Carion; D A Caugant; H Goossens
Journal:  J Clin Microbiol       Date:  1998-10       Impact factor: 5.948

3.  New Zealand epidemic of meningococcal disease identified by a strain with phenotype B:4:P1.4.

Authors:  D R Martin; S J Walker; M G Baker; D R Lennon
Journal:  J Infect Dis       Date:  1998-02       Impact factor: 5.226

4.  Multilocus sequence typing: a portable approach to the identification of clones within populations of pathogenic microorganisms.

Authors:  M C Maiden; J A Bygraves; E Feil; G Morelli; J E Russell; R Urwin; Q Zhang; J Zhou; K Zurth; D A Caugant; I M Feavers; M Achtman; B G Spratt
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-17       Impact factor: 11.205

5.  Phase I clinical trial with a hexavalent PorA containing meningococcal outer membrane vesicle vaccine.

Authors:  C C Peeters; H C Rümke; L C Sundermann; E M Rouppe van der Voort; J Meulenbelt; M Schuller; A J Kuipers; P van der Ley; J T Poolman
Journal:  Vaccine       Date:  1996-07       Impact factor: 3.641

6.  The maintenance of strain structure in populations of recombining infectious agents.

Authors:  S Gupta; M C Maiden; I M Feavers; S Nee; R M May; R M Anderson
Journal:  Nat Med       Date:  1996-04       Impact factor: 53.440

7.  Neisseria meningitidis is structured in clades associated with restriction modification systems that modulate homologous recombination.

Authors:  Sonia Budroni; Emilio Siena; Julie C Dunning Hotopp; Kate L Seib; Davide Serruto; Chiara Nofroni; Maurizio Comanducci; David R Riley; Sean C Daugherty; Samuel V Angiuoli; Antonello Covacci; Mariagrazia Pizza; Rino Rappuoli; E Richard Moxon; Hervé Tettelin; Duccio Medini
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-28       Impact factor: 11.205

8.  Immunogenicity and reactogenicity in UK infants of a novel meningococcal vesicle vaccine containing multiple class 1 (PorA) outer membrane proteins.

Authors:  K Cartwright; R Morris; H Rümke; A Fox; R Borrow; N Begg; P Richmond; J Poolman
Journal:  Vaccine       Date:  1999-06-04       Impact factor: 3.641

9.  Genetic structure of Neisseria meningitidis populations in relation to serogroup, serotype, and outer membrane protein pattern.

Authors:  D A Caugant; L F Mocca; C E Frasch; L O Frøholm; W D Zollinger; R K Selander
Journal:  J Bacteriol       Date:  1987-06       Impact factor: 3.490

10.  Proceedings of the Meningococcal Vaccine Strategy World Health Organization satellite meeting, 10 March 2004, Auckland, New Zealand.

Authors:  Kerry Sexton; Diana Lennon; Philipp Oster; Ingeborg Aaberge; Diana Martin; Stewart Reid; Sharon Wong; Jane O'Hallahan
Journal:  N Z Med J       Date:  2004-08-20
View more
  24 in total

Review 1.  Bexsero® chronicle.

Authors:  George Vernikos; Duccio Medini
Journal:  Pathog Glob Health       Date:  2014-10       Impact factor: 2.894

Review 2.  A deeper mining on the protein composition of VA-MENGOC-BC®: An OMV-based vaccine against N. meningitidis serogroup B and C.

Authors:  Yordanka Masforrol; Jeovanis Gil; Darien García; Jesús Noda; Yassel Ramos; Lázaro Betancourt; Osmany Guirola; Sonia González; Boris Acevedo; Vladimir Besada; Osvaldo Reyes; Luis Javier González
Journal:  Hum Vaccin Immunother       Date:  2017-10-30       Impact factor: 3.452

3.  Molecular Engineering of Ghfp, the Gonococcal Orthologue of Neisseria meningitidis Factor H Binding Protein.

Authors:  Valentina Rippa; Laura Santini; Paola Lo Surdo; Francesca Cantini; Daniele Veggi; Maria Antonietta Gentile; Eva Grassi; Giulia Iannello; Brunella Brunelli; Francesca Ferlicca; Emiliano Palmieri; Michele Pallaoro; Beatrice Aricò; Lucia Banci; Mariagrazia Pizza; Maria Scarselli
Journal:  Clin Vaccine Immunol       Date:  2015-05-06

4.  Susceptibility of Meningococcal Strains Responsible for Two Serogroup B Outbreaks on U.S. University Campuses to Serum Bactericidal Activity Elicited by the MenB-4C Vaccine.

Authors:  Raffaella Rossi; Peter T Beernink; Serena Giuntini; Dan M Granoff
Journal:  Clin Vaccine Immunol       Date:  2015-09-30

5.  Neisseria adhesin A variation and revised nomenclature scheme.

Authors:  Stefania Bambini; Matteo De Chiara; Alessandro Muzzi; Marirosa Mora; Jay Lucidarme; Carina Brehony; Ray Borrow; Vega Masignani; Maurizio Comanducci; Martin C J Maiden; Rino Rappuoli; Mariagrazia Pizza; Keith A Jolley
Journal:  Clin Vaccine Immunol       Date:  2014-05-07

6.  Meningococcal vaccine antigen diversity in global databases.

Authors:  Carina Brehony; Dorothea M Hill; Jay Lucidarme; Ray Borrow; Martin C Maiden
Journal:  Euro Surveill       Date:  2015

7.  Genetic Diversity of Meningococcal Serogroup B Vaccine Antigens among Carriage Isolates Collected from Students at Three Universities in the United States, 2015-2016.

Authors:  Henju Marjuki; How-Yi Chang; Nadav Topaz; Melissa J Whaley; Jeni Vuong; Alexander Chen; Laurel T Jenkins; Fang Hu; Susanna Schmink; Adam C Retchless; Jennifer D Thomas; Anna M Acosta; Lucy A McNamara; Heidi M Soeters; Sarah Mbaeyi; Xin Wang
Journal:  mBio       Date:  2021-05-18       Impact factor: 7.867

Review 8.  How the Knowledge of Interactions between Meningococcus and the Human Immune System Has Been Used to Prepare Effective Neisseria meningitidis Vaccines.

Authors:  R Gasparini; D Panatto; N L Bragazzi; P L Lai; A Bechini; M Levi; P Durando; D Amicizia
Journal:  J Immunol Res       Date:  2015-08-17       Impact factor: 4.818

9.  Nonfunctional variant 3 factor H binding proteins as meningococcal vaccine candidates.

Authors:  Stijn van der Veen; Steven Johnson; Ilse Jongerius; Talat Malik; Alessia Genovese; Laura Santini; David Staunton; Rafael L Ufret-Vincenty; Matthew C Pickering; Susan M Lea; Christoph M Tang
Journal:  Infect Immun       Date:  2013-12-30       Impact factor: 3.441

Review 10.  Broad vaccine protection against Neisseria meningitidis using factor H binding protein.

Authors:  Jamie Findlow; Christopher D Bayliss; Peter T Beernink; Ray Borrow; Paul Liberator; Paul Balmer
Journal:  Vaccine       Date:  2020-08-30       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.